Azevedo RS, Jen W-Y, Hammond D, Haddad FG, Geppner A, Issa GC, Sasaki K, Senapati J, Jabbour E, Ravandi F, Kantarjian H, Kadia TM. Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i&gt;-negative B-cell/myeloid mixed phenotype acute leukemia. Haematologica 2025;110(12):3129-3132; https://doi.org/10.3324/haematol.2025.287932.